NicOx and DSM collaborate on commercial manufacture of osteoarthritis drug substance
French biopharmaceutical company NicOx has signed an agreement with DSM for the commercial manufacture and supply of naproxcinod API.
French biopharmaceutical company NicOx has signed an agreement with DSM for the commercial manufacture and supply of naproxcinod API.
Naproxcinod is a leading NicOx investigational product and the first compound in the cyclooxygenase-inhibiting nitric oxide-donating (CINOD) class of anti-inflammatory agents, which recently achieved positive results in the third pivotal phase 3 study in osteoarthritis patients.
Under the terms of the agreement, DSM will supply naproxcinod API for commercial purposes from its production site in Linz, Austria.
DSM is a leading independent supplier to the pharmaceutical industry, with some 40% of today’s top-selling medicines containing ingredients developed and produced by the company.
The announcement follows NiOx’ agreement with Capsugel in September for the commercial manufacture of naproxcinod oral capsules.
Staffan Strömberg, vice president of technical development and operations at NicOx, said: ‘The latest positive results observed in the 111 and 303 studies support our confidence in naproxcinod’s blockbuster potential.’
NicOx envisages the first deliveries of significant quantities of commercial material being made from the fourth quarter of 2009. Following this agreement with DSM, NicOx has ended its present API supply agreement with Archimica.
